文献速递淋巴瘤白血病

Copanlisib与维奈克拉等药物在B细胞和T细胞淋巴瘤模型中协同增效

Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
PubMed 文献 · Blood Adv · 2020-01-01

研究在套细胞淋巴瘤、边缘区淋巴瘤和T细胞淋巴瘤的26株细胞系中筛选copanlisib单药及联合17种药物的活性,发现与BCL2抑制剂维奈克拉协同最强,并在MZL异种移植模型和MCL原代细胞中验证,协同机制与凋亡增加及MCL1/BCL-XL下调相关,支持SAKK 66/18 I期研究。

要点

  • Copanlisib单药在多数淋巴瘤模型中呈剂量依赖性抗肿瘤活性。
  • Copanlisib与维奈克拉协同最强,在MZL和MCL模型中验证。
  • 协同机制与凋亡增加及MCL1、BCL-XL降低相关。

核心结论

  • Copanlisib与维奈克拉在MCL、MZL和T细胞淋巴瘤模型中协同诱导凋亡,支持进一步临床探索。

研究设计与样本

  • 在26株源自套细胞淋巴瘤、边缘区淋巴瘤和T细胞淋巴瘤的细胞系中测试copanlisib单药及联合17种药物,并开展体内实验、转录组分析和免疫印迹。

主要发现

  • Copanlisib单药在绝大多数模型中显示剂量依赖性抗肿瘤活性。
  • 联合筛选发现多个化合物与copanlisib协同,其中与维奈克拉协同最强。
  • 联合获益在MZL异种移植模型和MCL原代细胞中验证,源于凋亡诱导增加。
  • 协同效应可能与MCL细胞系中MCL1降低和MZL细胞系中BCL-XL降低有关。

临床怎么用

  • 研究数据支持SAKK 66/18 I期研究,该研究正在复发/难治性淋巴瘤中探索copanlisib联合维奈克拉。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of targeted agents. Here, we searched for novel copanlisib-based combinations. Copanlisib was tested as a single agent, in combination with an additional 17 drugs in 26 cell lines derived from mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and T-cell lymphomas. In vivo experiments, transcriptome analyses, and immunoblotting experiments were also performed. Copanlisib as a single agent showed in vitro dose-dependent antitumor activity in the vast majority of the models. Combination screening identified several compounds that synergized with copanlisib. The strongest combination was with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax. The benefit of the combination over single agents was also validated in an MZL xenograft model and in MCL primary cells, and was due to increased induction of apoptosis, an effect likely sustained by the reduction of the antiapoptotic proteins myeloid cell leukemia 1 (MCL1) and BCL-XL, observed in MCL and MZL cell lines, respectively. These data supported the rationale for the design of the Swiss Group for Clinical Cancer Research (SAKK) 66/18 phase 1 study currently exploring the combination of copanlisib and venetoclax in relapsed/refractory lymphomas.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tarantelli C, Lange M, Gaudio E, et al. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Adv. 2020. PMID: 32126142. doi:10.1182/bloodadvances.2019000844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。